GlassScriptPhysician profile
Nancy C Germany
NPI 1760418131
$4,504.26
in general payments reported to CMS, 2019-2025
33 companies · $641 in 2025
The $641 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $1,189 · 2021: $217 · 2022: $625 · 2023: $511 · 2024: $490 · 2025: $641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,641.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $1,059.23 | 2020 | |
| Abbvie INC. | $1,016.53 | 2021-2025 | |
| Amgen INC. | $409.89 | 2019-2022 | |
| Pfizer INC. | $392.40 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $352.99 | 2019-2025 | Relistor |
| Biohaven Pharmaceutical Holding Company LTD. | $166.14 | 2022 | |
| Scilex Pharmaceuticals INC. | $132.75 | 2022-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $109.01 | 2019-2024 | Xtampza |
| Teva Pharmaceuticals USA, INC. | $105.59 | 2019-2020 | |
| Averitas Pharma INC. | $86.91 | 2024-2025 | Qutenza |
| Daiichi Sankyo INC. | $62.52 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $56.62 | 2019 | |
| Axsome Therapeutics, INC. | $54.59 | 2025 | Symbravo |
| Saluda Medical Americas, INC. | $53.92 | 2023-2025 | Evoke, Evoke Scs |
| Novartis Pharmaceuticals Corporation | $48.58 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $45.87 | 2021 | |
| Lilly USA, LLC | $37.67 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $33.39 | 2024-2025 | |
| Medtronic, INC. | $32.66 | 2024 | Corevalve Evolut R, Plasmablade(Tm) |
| Takeda Pharmaceuticals U.S.A., INC. | $27.96 | 2019 | |
| Gilead Sciences, INC. | $23.24 | 2024 | |
| Abbott Laboratories | $22.36 | 2025 | Eterna |
| Tonix Medicines, INC. | $22.00 | 2025 | Tonmya |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Baudax Bio INC. | $19.64 | 2020 | |
| Nalu Medical, INC. | $17.23 | 2024 | Nalu Neurostimulation System |
| Lundbeck LLC | $17.20 | 2024 | Vyepti |
| Boston Scientific Corporation | $16.61 | 2025 | Wavewriter Alpha Prime 16 |
| Arbor Pharmaceuticals, INC. | $13.36 | 2019 | |
| Nevro Corp. | $12.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.94 | 2022 | |
| Medtronic USA, INC. | $10.85 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Germany listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.